Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

1

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Peroxisome proliferator-activated receptor alpha

1

Peroxisome proliferator-activated receptor gamma

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase III

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Dyslipidemia

1

Type 2 diabetes mellitus

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Bristol-Myers Squibb

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

FDA UNII

2

PUBCHEM

2

ChEMBL

1

DRUG BANK

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

MURAGLITAZAR

W1MKM70WQI

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Peroxisome proliferator-activated receptor alpha

Peroxisome proliferator-activated receptor gamma

Conditions:

Type 2 diabetes mellitus

Muraglitazar previously known as BMS-298585 has been identified as a non-thiazolidinedione dual agonist of peroxisome proliferator-activated receptor alpha/gamma. Muraglitazar is currently in clinical trial phase III development for the treatment of ...

type 2 diabetes and dyslipidemia.

BMS-644950

ZBX3PZ7A0F

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1